A number of firms have modified their ratings and price targets on shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) recently:

  • 1/15/2018 – ACADIA Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. “
  • 1/10/2018 – ACADIA Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/9/2018 – ACADIA Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $30.00 price target on the stock. According to Zacks, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. “
  • 1/2/2018 – ACADIA Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. “
  • 12/27/2017 – ACADIA Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ ACAD) traded up $0.47 on Monday, reaching $28.37. 1,694,294 shares of the company’s stock were exchanged, compared to its average volume of 2,066,911. The company has a market capitalization of $3,470.00, a PE ratio of -11.53 and a beta of 3.79. ACADIA Pharmaceuticals Inc. has a 1 year low of $25.06 and a 1 year high of $41.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.10. The firm had revenue of $35.58 million during the quarter, compared to analysts’ expectations of $32.03 million. ACADIA Pharmaceuticals had a negative net margin of 320.71% and a negative return on equity of 67.68%. The company’s revenue for the quarter was up 571.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.61) earnings per share. research analysts predict that ACADIA Pharmaceuticals Inc. will post -2.41 earnings per share for the current year.

In other news, Director Laura Brege sold 25,000 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $30.06, for a total value of $751,500.00. Following the completion of the transaction, the director now owns 15,000 shares in the company, valued at $450,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Glenn Baity sold 74,321 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $30.14, for a total transaction of $2,240,034.94. The disclosure for this sale can be found here. 22.25% of the stock is owned by company insiders.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Receive News & Ratings for ACADIA Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.